AngioDynamics, Inc. (ANGO)
15.78
+0.03
(+0.19%)
USD |
NASDAQ |
Aug 24, 16:00
15.78
0.00 (0.00%)
After-Hours: 20:00
AngioDynamics Enterprise Value : 613.87M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 613.87M |
| August 20, 2026 | 616.79M |
| August 19, 2026 | 627.22M |
| August 18, 2026 | 616.79M |
| August 17, 2026 | 610.54M |
| August 14, 2026 | 618.04M |
| August 13, 2026 | 610.12M |
| August 12, 2026 | 613.87M |
| August 11, 2026 | 613.87M |
| August 10, 2026 | 613.87M |
| August 07, 2026 | 611.37M |
| August 06, 2026 | 587.18M |
| August 05, 2026 | 584.27M |
| August 04, 2026 | 590.52M |
| August 03, 2026 | 589.69M |
| July 31, 2026 | 573.84M |
| July 30, 2026 | 573.01M |
| July 29, 2026 | 567.17M |
| July 28, 2026 | 555.08M |
| July 27, 2026 | 526.72M |
| July 24, 2026 | 523.80M |
| July 23, 2026 | 517.55M |
| July 22, 2026 | 533.39M |
| July 21, 2026 | 550.07M |
| July 20, 2026 | 528.80M |
| Date | Value |
|---|---|
| July 17, 2026 | 520.46M |
| July 16, 2026 | 546.74M |
| July 15, 2026 | 560.50M |
| July 14, 2026 | 499.20M |
| July 13, 2026 | 489.81M |
| July 10, 2026 | 490.44M |
| July 09, 2026 | 495.86M |
| July 08, 2026 | 491.27M |
| July 07, 2026 | 502.12M |
| July 06, 2026 | 498.36M |
| July 02, 2026 | 502.95M |
| July 01, 2026 | 502.53M |
| June 30, 2026 | 499.61M |
| June 29, 2026 | 507.54M |
| June 26, 2026 | 515.88M |
| June 25, 2026 | 526.72M |
| June 24, 2026 | 497.11M |
| June 23, 2026 | 472.93M |
| June 22, 2026 | 473.76M |
| June 18, 2026 | 463.75M |
| June 17, 2026 | 446.65M |
| June 16, 2026 | 463.75M |
| June 15, 2026 | 456.66M |
| June 12, 2026 | 461.67M |
| June 11, 2026 | 460.83M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Boston Scientific Corp. | 85.09B |
| Penumbra, Inc. | 12.36B |
| Abbott Laboratories | 229.49B |
| Alphatec Holdings, Inc. | 1.956B |
| AtriCure, Inc. | 2.398B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.40M |
| Revenue (Quarterly) | 86.61M |
| Total Expenses (Quarterly) | 98.01M |
| EPS Diluted (Quarterly) | -0.2735 |
| Gross Profit Margin (Quarterly) | 50.87% |
| Profit Margin (Quarterly) | -13.17% |
| Earnings Yield | -5.61% |
| Normalized Earnings Yield | -3.791 |